ORGANON & CO. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.55 USD | +0.71% |
|
+4.10% | +28.64% |
| 09/04 | Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating | MT |
| 08/04 | Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint | MT |
| Sales 2024 * | 6.37B 531B | Sales 2025 * | 6.46B 538B | Capitalization | 4.77B 398B |
|---|---|---|---|---|---|
| Net income 2024 * | 788M 65.7B | Net income 2025 * | 981M 81.79B | EV / Sales 2024 * | 1.92 x |
| Net Debt 2024 * | 7.5B 625B | Net Debt 2025 * | 6.83B 569B | EV / Sales 2025 * | 1.8 x |
| P/E ratio 2024 * |
6.1
x | P/E ratio 2025 * |
4.89
x | Employees | 10,000 |
| Yield 2024 * |
5.97% | Yield 2025 * |
6.2% | Free-Float | 99.86% |
More Fundamentals
* Assessed data
More news
Latest transcript on Organon & Co.
More recommendations
More press releases
More news
| 1 day | +0.71% | ||
| 1 week | +4.10% | ||
| Current month | -1.33% | ||
| 1 month | +2.37% | ||
| 3 months | +10.88% | ||
| 6 months | +21.16% | ||
| Current year | +28.64% |
1 week
17.79
18.75
1 month
17.3318.93
Current year
13.6519.08
1 year
10.8424.79
3 years
10.8439.48
5 years
10.8439.48
10 years
10.8439.48
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Ali
CEO | Chief Executive Officer | 63 | 02/21/02 |
Matthew Walsh
DFI | Director of Finance/CFO | 57 | 02/21/02 |
| Chief Tech/Sci/R&D Officer | 54 | 05/23/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rochelle Lazarus
BRD | Director/Board Member | 76 | 02/21/02 |
Carrie Cox
CHM | Chairman | 66 | 02/21/02 |
Robert Essner
BRD | Director/Board Member | 76 | 02/21/02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.92% | 215 M€ | +10.68% | - | |
| 1.71% | 2 M€ | +6.77% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 18.55 | +0.71% | 2,049,767 |
| 25/24/25 | 18.42 | -1.55% | 1,541,861 |
| 24/24/24 | 18.71 | +1.03% | 1,999,344 |
| 23/24/23 | 18.52 | +2.89% | 1,699,256 |
| 22/24/22 | 18 | +1.01% | 1,551,049 |
Delayed Quote Nyse, April 27, 2024 at 01:30 am IST
More quotes
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Companyâs Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
Sector
Pharmaceuticals
Calendar
02/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
18.55
USD
Average target price
21.5
USD
Spread / Average Target
+15.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.64% | 4.77B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- OGN Stock
